BioNTech SE
For the six months ended June 30, 2023, total revenues were €1.44 billion, compared to €9.6 billion for the comparative prior year period.
Write-offs by BioNTech's collaboration partner Pfizer Inc
Cash and cash equivalents and security investments were €14.17 billion and €2.7 billion, respectively.
After the end of the reporting period, the payment settling BioNTech's gross profit share for Q1 of 2023 (as defined by the contract with Pfizer) in the amount of €1.06 billion was received from BioNTech's collaboration partner as of July 17, 2023.
In addition, until early August 2023, €437.7 million was received in connection with the amended COVID-19 Vaccine Purchase Agreement with the European Commission.
The company incurred an EPS loss of €(0.79) compared to an income of €6.45 a year ago.
"Simultaneously, we are enhancing our infectious disease pipeline to address global health needs and are developing an Omicron XBB.1.5-adapted monovalent COVID-19 vaccine to become available for the upcoming fall-winter season, subject to regulatory approvals," said Prof. Ugur Sahin, CEO, and Co-Founder.
It expects R&D expenses of €2-€2.2 billion, down from prior guidance of €2.4-€2.6 billion, and Capex of €350- €450 million, down from prior guidance of €500-€600 million.
Price Action: BNTX shares are down 8.65% at $97.33 on the last check Monday.
